Axsome Therapeutics (NASDAQ:AXSM)‘s stock had its “buy” rating restated by analysts at William Blair in a note issued to investors on Thursday, AnalystRatings.com reports. AXSM has been the subject of a number of other reports. Bank of America started coverage on shares of Axsome Therapeutics in a report on Tuesday. They issued an “underperform” rating […]
